IP Library › Granted Patent US 10,881,625
Granted Patent B2
US 10,881,625 · App. 16/598,509 · Granted Jan 5, 2021

Combination treatments for opioid crisis

Inventor: Michael Presti (Jacksonville, OR)
A61K31/145A61K31/137A61K31/4468A61K31/485A61P25/04A61P25/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,625
App. No.
16/598,509
Granted
Jan 5, 2021
Kind
B2
Abstract

A method of reducing the risk of medication-related overdose, death, or other injury associated with inappropriate consumption of alcohol in conjunction with prescription opioid analgesics, comprising: administering a combination medication having an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors, in order to provide the powerful analgesic effects of the opioid in conjunction with a substance that prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death. A combination medication, including an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier.

Claims (16)

1. A combination medication, comprising:

an effective amount of one or more opioid medications; and

an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier, wherein the one or more aldehyde dehydrogenase inhibitors is selected from one or more of disulfiram, calcium carbimide, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporins, antidiabetic sulfonyl ureas, metronidazole, ampal, benomyl, citral and active isomers thereof, chloral hydrate, chlorpropamide analogs (benzoyloxy)[4-chlorophenyl)sulfonyl]carbamic acid 1,1-dimethylethyl ester (NPI-1) and 4-chloro-N-ethyl-N-[(propylamino)carbonyl]benzenesulfonamid (API-1), 3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid (CVT-10216), N,N-diethylaminobenzaldehyde (DEAB), gossypol, kynurenine tryptophan metabolites, molinate, nitroglycerin, pargyline, S-methyl N,N-diethyldithiocarbamate, S-methyl N,N-diethyldithiocarbamate sulfoxide, and S-methyl N,N-diethylthiocarbamate sulfoxide, HNO, 1-aminocyclopropanol ACP, thioampal, 2-mercaptobenzothiazole (MBT), molinate sulfoxide, molinate sulfone, NO3, propiolaldehyde, or pharmaceutically acceptable salts thereof.

2. The combination medication of claim 1 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, and/or pharmaceutically acceptable salts thereof.

3. The combination medication of claim 1 , the aldehyde dehydrogenase inhibitor consists essentially of disulfiram, and/or pharmaceutically acceptable salts thereof.

4. The combination medication of claim 1 , wherein the one or more opioid medications is one or more prescription opioid analgesics.

5. The combination medication of claim 1 , wherein the one or more opioid medications is one or more of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, sufentanil, tilidine, and tramadol.

6. The combination medication of claim 5 , wherein the one or more opioid medications is morphine, methadone, hydrocodone, oxycodone, fentanyl, hydromorphone, or codeine.

7. The combination medication of claim 5 , wherein the one or more opioid medications consists essentially of one or more of morphine, methadone, hydrocodone, hydromorphone, oxymorphone, oxycodone, fentanyl, or codeine.

8. A combination medication, comprising:

an effective amount of oxycodone; and

an effective amount of disulfiram or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

9. The combination medication of claim 5 , wherein the one or more opioid medication is hydrocodone and the one or more aldehyde dehyrogenase inhibitors is disulfiram or a pharmaceutically acceptable salt thereof.

10. The combination medication of claim 5 , wherein the one or more opioid medications is morphine and the one or more aldehyde dehyrogenase inhibitors is disulfiram or a pharmaceutically acceptable salt thereof.

11. The combination medication of claim 5 , wherein the one or more opioid medications is methadone and the one or more aldehyde dehyrogenase inhibitors is disulfiram or a pharmaceutically acceptable salt thereof.

12. The combination medication of claim 1 , wherein the one or more opioid medication is buprenorphine and the one or more aldehyde dehyrogenase inhibitors is disulfiram or a pharmaceutically acceptable salt thereof.

Continuity (2)
Division 15881475 · Jan 26, 2018
Related Publication 20200038346A1 · Feb 6, 2020